- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
A Setback for Fasenra As a Treatment Chronic Rhinosinusitis With Nasal Polyps
The FDA issued a complete response letter, so AstraZeneca’s monoclonal antibody won’t be joining Nucala and Dupixent as treatments for chronic rhinosinusitis with nasal polyps anytime soon.
AstraZeneca announced today that the FDA has not accepted its application to have Fasenra (benralizumab), a monoclonal antibody already approved for asthma, be additionally approval as a treatment for chronic rhinosinusitis with nasal polyps.
But the company said in a news release that it was committed to moving ahead with Fasenra as a treatment for chronic rhinosinusitis with nasal polyps and that a second phase 3 trial, dubbed ORCHID, is underway.
AstraZeneca used results from a prior phase 3 trial, called OSTRO, in the application that led to the FDA issuing a complete response letter.
The FDA issues a complete response letter when it finds shortcomings in a drug developer’s application. The shortcomings can range from minor problems that are easily remedied or major ones that require a new clinical trial or signal a serious problem with the drug. AstraZeneca’s news release didn’t have any details on the reason for the FDA’s complete response letter.
The competition among monoclonal antibody to be used as treatments for chronic rhinosinusitis with nasal polyps is heating up, and the spin on the news about the FDA complete response letter was that Fasenra was falling behind. The FDA approved GlaxoSmithKline’s Nucala (mepolizumab) as a treatment in July 2021 and Sanofi and Regeneron’s Dupixent (dupilumab) in June 2019.
“AstraZeneca’s Fasenra is already late to the game in nasal polyps, and now the drug is being pushed back even further — if it can eventually get there,” reported Fierce Pharma.
Black/African American Patients With Atopic Dermatitis Report Improvements, Satisfaction on Dupixent
November 2nd 2023A subgroup analysis of real-world patient survey data found Black/African American patients with moderate to severe atopic dermatitis had improved disease control, symptoms and treatment satisfaction on Dupixent.
Read More
In Type 2 Inflammation, an Unexpected Relationship Between Itchiness and Inflammation
October 26th 2023When interleukin (IL)-31 stimulates nerves that create itchiness it may also have a downstream effect that tempers inflammatory processes, according to mouse model research done by investigators at the University of California, San Francisco.
Read More
